Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
17
Jan |
News From The Annals Of Internal Medicine: Jan. 17, 2012Category: COPD | Leave a Comment |
1. High Doses of Vitamin D Provide No Benefit to Patients with Severe COPD Chronic obstructive pulmonary disease (COPD) is one of the top 10 leading causes of morbidity and mortality in the United States. Vitamin D deficiency is present in 60 percent to 75 percent of patients with severe COPD…
|
27
May |
Phase III Data Showed Novartis Investigational Bronchodilator QAB149 Significantly Improved Lung Function In COPD PatientsCategory: COPD | Leave a Comment |
The Novartis investigational bronchodilator QAB149 (indacaterol) met the primary efficacy endpoints of improved lung function compared to placebo at 12 weeks in three pivotal phase III studies in chronic obstructive pulmonary disease (COPD) patients. In secondary endpoints of these studies, QAB149 demonstrated clinically relevant lung function improvements within five minutes of the first dose, lasting for 24 hours in COPD patients.